{
    "relation": [
        [
            "",
            "CP-690,550 5 mg",
            "CP-690,550 10 mg",
            "Placebo, Then CP-690,550 5 mg",
            "Placebo, Then CP-690,550 10 mg"
        ],
        [
            "Description",
            "CP-690,550 5 mg tablet orally twice daily up to Month 6.",
            "CP-690,550 10 mg tablet orally twice daily up to Month 6.",
            "Placebo matched to CP-690,550 tablet orally twice daily up to Month 3 followed by CP-690,550 5 mg tablet orally twice daily up to Month 6.",
            "Placebo matched to CP-690,550 tablet orally twice daily up to Month 3 followed by CP-690,550 10 mg tablet twice daily orally up to Month 6."
        ]
    ],
    "pageTitle": "Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00960440?sect=Xlm015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988860.88/warc/CC-MAIN-20150728002308-00162-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 883387999,
    "recordOffset": 883370995,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details No text entered. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: CP-690,550 Drug: Placebo Interventions: Arthritis, Rheumatoid Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Caregiver,\u00a0Investigator,\u00a0Outcomes\u00a0Assessor); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional Study Type: Results First Received: December 6, 2012 \u00a0",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 CP-690,550 5 mg \u00a0 \u00a0 CP-690,550 10 mg \u00a0 \u00a0 Placebo, Then CP-690,550 5 mg \u00a0 \u00a0 Placebo, Then CP-690,550 10 mg \u00a0 STARTED \u00a0 \u00a0 133 \u00a0 \u00a0 134 \u00a0 \u00a0 66 \u00a0 \u00a0 66 \u00a0 COMPLETED \u00a0 \u00a0 107 \u00a0 \u00a0 103 \u00a0 \u00a0 53 \u00a0 \u00a0 48 \u00a0 NOT COMPLETED \u00a0 \u00a0 26 \u00a0 \u00a0 31 \u00a0 \u00a0 13 \u00a0 \u00a0 18 \u00a0 Death \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}